Across TCGA pan-cancer cohorts, C20orf197 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C20orf197 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher C20orf197 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C20orf197 expression acts as an unfavorable survival marker.
LUSC are the cancer types where C20orf197 Mutation most reproducibly stratifies survival.